Biotechnology Recall Procedures Law In Russia.

1. Introduction

Biotechnology recall procedures in Russia refer to the legal and administrative mechanisms through which unsafe, defective, non-compliant, contaminated, improperly labelled, or unlawfully distributed biotechnology products are withdrawn from the market or recovered from consumers, hospitals, pharmacies, laboratories, and distributors.

The framework is particularly important for:

Vaccines and biological medicines.

Genetically engineered medicinal products.

Recombinant proteins and monoclonal antibodies.

Blood products and plasma-derived medicines.

Gene and cell therapy products.

Diagnostic biotechnology products.

Genetically modified organisms (GMOs).

Biotechnology-derived food and agricultural products.

Russian law does not establish one universal recall statute covering every category of biotechnology. Instead, recall obligations arise from several overlapping legal regimes governing pharmaceutical products, consumer protection, technical regulation, sanitary safety, food safety, and genetically engineered organisms.

The central legal objective is to protect human health, prevent further distribution of dangerous products, ensure traceability, and establish accountability among manufacturers, importers, distributors, and regulatory authorities.

2. Principal legislative framework

The main Russian laws governing biotechnology product recalls are as follows.

LegislationLegal significance
Federal Law No. 61-FZ of 12 April 2010, On Circulation of MedicinesPharmaceutical and biological medicine quality, safety, suspension and withdrawal.
Federal Law No. 2300-1 of 7 February 1992, On Protection of Consumer RightsConsumer safety, withdrawal of dangerous products and compensation.
Federal Law No. 184-FZ of 27 December 2002, On Technical RegulationCorrective action programmes and recall of non-compliant products.
Federal Law No. 52-FZ of 30 March 1999, On Sanitary and Epidemiological Welfare of the PopulationPublic-health protection and sanitary controls.
Federal Law No. 86-FZ of 5 July 1996, On State Regulation in the Field of Genetic Engineering ActivitiesRegulation of genetically engineered organisms and activities.
Federal Law No. 29-FZ of 2 January 2000, On Quality and Safety of Food ProductsSafety requirements for biotechnology-derived food products.
Federal Law No. 3-FZ of 8 January 1998, On Narcotic Drugs and Psychotropic SubstancesRelevant where biotechnology products contain regulated substances.

The most important legislation for biological medicinal products is Federal Law No. 61-FZ.

3. Recall procedures under Federal Law No. 61-FZ

Federal Law No. 61-FZ regulates the complete life cycle of medicinal products, including biological medicines, manufacturing, quality control, storage, transportation, distribution, use and destruction.

Its principal objectives are:

Preventing circulation of defective medicinal products.

Ensuring pharmaceutical quality and safety.

Monitoring adverse reactions.

Protecting patients from unsafe biological medicines.

Establishing regulatory supervision over manufacturers and distributors.

Section 57 – Prohibition on the sale of certain medicinal products

Article 57 prohibits the sale of falsified, substandard and counterfeit medicinal products. It also restricts the sale of medicines whose use has been suspended, whose circulation has been terminated, or which are otherwise prohibited under the statutory conditions.

This provision is particularly important for biotechnology products because contamination, incorrect biological composition, manufacturing deviations and improper storage can make a medicinal batch unsuitable for circulation.

Consultant Plus+1

 

Section 59 – Withdrawal and destruction

Article 59 provides for the withdrawal from circulation and destruction of substandard and falsified medicines.

Destruction may be based on:

A decision of the product owner.

A decision of the competent federal executive authority.

A judicial decision.

This is important for vaccines, recombinant proteins, biological injectables and other products whose quality cannot be restored through ordinary corrective action.

Consultant Plus

 

Section 64 – Pharmacovigilance

Article 64 establishes pharmacovigilance for medicinal products circulating in Russia.

It requires monitoring of:

Adverse drug reactions.

Serious adverse reactions.

Unexpected adverse reactions.

Individual intolerance.

Lack of therapeutic effectiveness.

Other circumstances threatening human or animal health.

Marketing authorisation holders and other regulated participants have reporting and safety-management responsibilities.

Where serious safety information emerges, the marketing authorisation holder must take measures to prevent harm and protect patients. The competent authority can consider suspension of the medicine's use.

Consultant Plus+1

 

4. Regulatory authorities responsible for biotechnology recalls

A. Roszdravnadzor – Federal Service for Surveillance in Healthcare

Roszdravnadzor is the principal supervisory authority for medicinal products intended for human use.

Its responsibilities include:

Monitoring medicine quality and safety.

Investigating quality defects.

Publishing notices about medicines withdrawn from circulation.

Monitoring adverse reactions.

Supervising compliance with pharmaceutical requirements.

Communicating regulatory decisions to market participants.

Its official medicines portal provides information about products withdrawn from circulation and quality-control notices.

roszdravnadzor.gov.ru+1

 

B. Ministry of Health of the Russian Federation

The Ministry of Health of the Russian Federation has responsibilities concerning state registration and regulatory decisions relating to medicinal products, including decisions concerning suspension of use and registration status.

C. Rospotrebnadzor

Rospotrebnadzor supervises consumer protection and sanitary and epidemiological requirements.

It is particularly relevant where contaminated biotechnology-derived foods or products create risks to public health.

D. Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor)

Rosselkhoznadzor is relevant to veterinary biological medicines, animal vaccines, genetically modified agricultural materials and products falling within its regulatory competence.

5. Step-by-step biotechnology recall procedure

A biotechnology recall generally involves the following stages.

Identification of a defect

A defect may be identified through laboratory testing, adverse-event reporting, manufacturing inspections, hospital complaints, distribution monitoring or foreign regulatory alerts.

Examples include bacterial contamination, incorrect dosage, loss of vaccine potency, defective packaging and deviations in biological composition.

Risk assessment

The manufacturer and relevant regulatory authority assess the nature and seriousness of the risk.

Factors include the severity of possible injury, number of affected batches, patient exposure, product stability and geographical distribution.

Suspension of distribution

Affected products may be quarantined, blocked or suspended from further distribution and use, depending on the applicable legal decision.

Article 57 of Federal Law No. 61-FZ is particularly important when the medicine's circulation has been suspended or terminated.

Notification of authorities and customers

The manufacturer, marketing authorisation holder, importer or distributor communicates relevant information to the authorities and affected supply-chain participants.

Notices should identify the product, batch numbers, expiry dates, risks and necessary precautions.

Product recovery

The affected batches are traced and recovered from pharmacies, hospitals, laboratories, distributors and other recipients.

For biological medicines, temperature-controlled transport and storage records may be particularly important.

Investigation and corrective action

The manufacturer investigates the root cause, examines production records, validates corrective measures and determines whether additional batches are affected.

Destruction or other lawful disposition

Products established to be substandard or falsified are dealt with under Article 59 and applicable government procedures.

Regulatory closure

The relevant authority evaluates corrective measures, quality evidence and the safety implications before any permissible resumption of circulation.

Importantly, this is a practical compliance sequence rather than a single statutory procedure with identical steps and deadlines for every biotechnology product.

6. Consumer protection and recall obligations

The Russian Consumer Protection Law No. 2300-1 provides another important foundation.

Article 7 – Right to product safety

Article 7 requires products to be safe under ordinary conditions of use, storage, transportation and disposal.

Under Article 7(5), where a product is found to cause or potentially cause harm despite compliance with prescribed conditions of use, storage or transportation, the manufacturer, seller or other responsible participant must promptly suspend production or sale until the danger is addressed.

Where necessary, the product must be removed from circulation and recalled from consumers.

If the danger cannot be eliminated, the manufacturer must discontinue production. Losses caused to consumers by the recall are subject to compensation.

Consultant Plus+1

 

Article 14 – Compensation for harm

Article 14 provides a basis for compensation for damage caused by defective or unsafe goods.

For example, if a contaminated biotechnology-derived medicine causes injury to a patient, the injured person may pursue compensation subject to the applicable liability requirements.

Article 18 – Consumer remedies

Consumers may exercise statutory remedies concerning defective products, subject to the nature of the product and applicable legal restrictions.

For medicines, safety-related withdrawal and destruction requirements must be distinguished from ordinary consumer exchange or replacement rights.

7. Recall obligations under the Technical Regulation Law

Federal Law No. 184-FZ is particularly relevant to biotechnology products that fall within the scope of applicable technical regulations.

Its recall-related provisions require manufacturers, sellers and persons performing the functions of foreign manufacturers to take corrective measures when non-compliance with technical regulations is confirmed.

Under Article 38, a programme of measures to prevent harm must be developed within ten days after confirmation of the relevant information and coordinated with the competent supervisory authority.

The programme must address:

Informing purchasers and consumers about the danger.

Explaining how harm can be prevented.

Establishing implementation deadlines.

Taking corrective measures.

Arranging product recall where necessary.

Where preventive measures cannot be implemented, the responsible parties must announce a recall and compensate purchasers for resulting losses.

Rosgvardiya+1

 

This framework is significant for biotechnology-derived products that are subject to mandatory technical requirements.

8. Biotechnology-specific recall situations

Different biotechnology products create different legal risks.

Biotechnology productPossible recall reasonRegulatory concern
VaccinesContamination or loss of potencyPatient safety
Gene therapyUnexpected safety risksSerious adverse effects
Recombinant proteinsIncorrect biological compositionQuality and effectiveness
Monoclonal antibodiesManufacturing defectsProduct safety
Blood-derived productsPathogen contaminationInfection prevention
Genetically modified foodSafety or labelling violationsConsumer and environmental protection
Veterinary vaccinesContamination or reduced effectivenessAnimal health
Diagnostic kitsIncorrect test resultsDiagnostic reliability

Special issue: GMO products

Russia has a separate regulatory framework for genetically engineered organisms under Federal Law No. 86-FZ and related legislation.

Where GMO-containing products violate applicable safety, registration, transportation or labelling requirements, regulatory authorities may take enforcement measures, including restrictions on circulation and removal of non-compliant products.

The GMO regime should not be confused with pharmaceutical recalls under Federal Law No. 61-FZ. The applicable procedure depends on whether the product is a medicinal product, food product, agricultural organism or research material.

9. Important judicial decisions and case laws

Russian biotechnology recall litigation is relatively specialised. There is no well-established Supreme Court doctrine specifically devoted to a comprehensive recall procedure for gene therapies, recombinant medicines or biotechnology products.

Nevertheless, several judicial decisions provide useful guidance on pharmaceutical withdrawal, regulatory authority, vaccine-related products and registration disputes.

Case 1: Twelfth Arbitration Court of Appeal, 1 February 2024

CASE NO. А12-25339/2023 · APPEAL NO. 12АП-10241/23

ГАРАНТ

This case concerned the regulatory supervision of medicinal-product quality by Roszdravnadzor.

The proceedings addressed the authority's power to communicate information about non-compliance with mandatory pharmaceutical quality requirements and the obligations of market participants to stop circulation of substandard medicines under Article 57 of Federal Law No. 61-FZ.

Legal significance:

Pharmaceutical quality supervision is a statutory regulatory responsibility.

Regulatory communications about defective medicines have practical consequences for market participants.

Distribution participants must respond to applicable restrictions on circulation.

Public-health protection is an important consideration in pharmaceutical supervision.

This decision is particularly relevant to understanding how quality-control findings can trigger the withdrawal process.

Case 2: Arbitration proceedings, Case No. А11-5337/2019

COURT OF THE VOLGO-VYATKA DISTRICT · DECISION OF 13 MARCH 2023

sudact.ru

This dispute involved the supply of a semi-finished rabies vaccine product.

The litigation concerned transactions involving 300,000 doses of vaccine semi-finished product, including 277,500 doses that remained unsold. The court proceedings considered the fact that the product's 18-month shelf life had expired.

Legal significance:

Biological products have limited shelf lives.

Expired vaccine materials cannot simply be treated as usable inventory.

Contractual disputes involving biological products require consideration of their specific characteristics.

Where physical restitution is impossible, monetary consequences may arise.

This is a useful biotechnology supply-chain and product-liability example, although it is not a direct judicial ruling establishing a general statutory recall procedure.

Case 3: Arbitration Court, Case No. А40-86939/2024

DECISION OF 23 JULY 2024

sudact.ru

The dispute concerned the registration of a medicinal product identified as Cefepime + Sulbactam.

The proceedings addressed the legal limits of the Ministry of Health's authority when considering expert assessments and the withdrawal or cancellation of a medicinal-product registration certificate.

The judgment discussed circumstances in which registration may be cancelled, including:

An application by the registration certificate holder.

Failure to comply with requirements imposed by the competent authority.

Failure to correct identified manufacturing or quality-control deficiencies.

Legal significance:

This case demonstrates the distinction between:

Withdrawal of an individual batch from circulation.

Suspension of a medicinal product's use.

Cancellation of the product's marketing authorisation.

These are different legal actions and should not be treated as interchangeable.

10. Administrative, civil and criminal liability

Failure to comply with biotechnology recall obligations may result in several forms of legal responsibility.

A. Administrative liability

Under the Russian Code of Administrative Offences, administrative sanctions may arise from:

Violations of pharmaceutical circulation requirements.

Manufacturing or distributing substandard medicines.

Violations of sanitary requirements.

Improper GMO handling or labelling.

Failure to comply with regulatory orders.

Depending on the violation, penalties may include fines, confiscation and suspension of activities.

B. Civil liability

Manufacturers, importers and other responsible parties may face compensation claims arising from defective biotechnology products.

Potential compensation includes:

Medical treatment expenses.

Lost income.

Property losses.

Other legally recoverable damages.

Moral damages where applicable.

C. Criminal liability

Where conduct satisfies the elements of a criminal offence, criminal responsibility may arise.

Potentially relevant provisions of the Criminal Code of the Russian Federation include:

Article 238 – Production, storage, transportation or sale of goods and products that do not meet safety requirements.

Article 236 – Violation of sanitary and epidemiological rules resulting in the consequences specified by the provision.

Article 109 – Causing death by negligence.

Article 118 – Causing serious harm to health through negligence.

Criminal liability requires proof of the relevant statutory elements; a defective product or unsuccessful recall does not automatically establish a criminal offence.

11. Cross-border biotechnology recalls

Cross-border biotechnology recalls are particularly important when Russian manufacturers export vaccines, biological medicines, diagnostic kits and recombinant products.

Three major legal issues arise.

1. International regulatory coordination

A product manufactured in Russia may be distributed in several countries. A safety problem identified in one country may require investigation and corrective action in other markets.

2. Eurasian Economic Union (EAEU) requirements

Russia participates in the Eurasian Economic Union pharmaceutical regulatory framework.

The EAEU rules governing registration, pharmacovigilance, quality and good manufacturing practices are relevant to biological medicinal products circulating within the Union.

The applicable EAEU requirements must be considered alongside Russian national legislation.

3. Foreign recall notifications

A manufacturer may receive a foreign regulatory warning concerning:

Contaminated biological material.

Unexpected adverse reactions.

Manufacturing deficiencies.

Defective packaging.

Inaccurate product information.

Such information can be relevant to Russian pharmacovigilance under Article 64 of Federal Law No. 61-FZ. Foreign recall information does not automatically produce an identical Russian legal decision; the competent authority must apply the relevant Russian and EAEU procedures.

12. Major legal challenges

Several challenges affect the practical implementation of biotechnology recall procedures in Russia.

Legal challengeExplanation
Batch traceabilityIdentifying all recipients of defective biological products.
Cold-chain failuresDetermining whether temperature deviations affected product quality.
Delayed reportingPreventing manufacturers from withholding adverse-event information.
Scientific uncertaintyEstablishing whether a suspected defect creates a genuine safety risk.
International distributionCoordinating corrective measures across multiple jurisdictions.
Recall costsDetermining responsibility for recovery, storage and destruction.
Patient notificationCommunicating risks without creating unnecessary public-health confusion.
Regulatory transparencyEnsuring clear and timely communication of recall decisions.

13. Hypothetical legal illustration

Consider a Russian biotechnology manufacturer producing a recombinant vaccine.

Following distribution, laboratory investigations identify contamination in one manufacturing batch.

The following legal consequences may arise:

The manufacturer investigates the contamination and identifies the affected batch.

Distribution and use are suspended where required.

Roszdravnadzor is informed and may initiate regulatory measures.

Hospitals, pharmacies and distributors receive instructions concerning the affected batch.

The product is recovered from the supply chain.

The manufacturer investigates the source of contamination.

The defective product is destroyed in accordance with Article 59 of Federal Law No. 61-FZ.

Affected patients may pursue compensation if legally established harm has occurred.

The regulator evaluates whether additional batches or the wider product authorisation are affected.

This example demonstrates the interaction between pharmaceutical regulation, pharmacovigilance, product safety and civil liability.

14. Critical legal analysis

The Russian biotechnology recall framework rests on three important legal principles.

First: Preventive protection of public health.

The law does not require authorities and manufacturers to wait until widespread injury occurs before taking appropriate safety measures. Evidence of potential harm can justify suspension and recall measures.

Second: Accountability throughout the supply chain.

Manufacturers, marketing authorisation holders, importers and distributors have different responsibilities. A manufacturer cannot necessarily avoid responsibility by transferring products to an intermediary.

Third: Scientific evidence and regulatory proportionality.

Not every adverse event requires a complete product recall. Regulators must distinguish between isolated reactions, manufacturing defects, storage failures and risks affecting an entire product or particular batches.

A targeted batch withdrawal may be appropriate in one situation, whereas a broader suspension or cancellation may be necessary in another.

15. Conclusion

Biotechnology Recall Procedures Law in Russia is based on a combination of pharmaceutical regulation, consumer protection, technical regulation, sanitary legislation and genetic-engineering controls.

Federal Law No. 61-FZ is the principal legislation for biotechnology-derived medicinal products, particularly through Articles 57, 59 and 64. Federal Law No. 2300-1 establishes consumer safety and recall responsibilities, while Federal Law No. 184-FZ provides an additional corrective-action and recall framework for products subject to technical regulations.

The judicial decisions discussed above demonstrate the importance of pharmaceutical quality supervision, biological-product shelf-life requirements and the distinction between batch withdrawal and cancellation of registration.

Ultimately, the effectiveness of Russian biotechnology recall law depends on timely scientific investigation, accurate batch traceability, transparent regulatory communication, effective product recovery and appropriate compensation for persons harmed by defective products.

16. Important legal research sources

For further academic and case-law research, the following official and legal databases are useful:

Official Internet Portal of Legal Information of Russia – Federal legislation and government regulations.

Roszdravnadzor – Pharmaceutical safety and withdrawal notices.

Rospotrebnadzor – Consumer protection and sanitary regulation.

SudAct – Russian judicial decisions.

ConsultantPlus – Russian legislation and legal commentary.

WIPO Lex – Russian intellectual property and related legislative materials.

Academic research note: The cases above should be cited according to their actual subject matter. They are useful pharmaceutical and biotechnology-related judicial authorities, but should not be represented as Supreme Court judgments establishing a universal biotechnology recall doctrine.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT